Arrowhead Pharmaceuticals... (ARWR)
NASDAQ: ARWR
· Real-Time Price · USD
13.26
0.20 (1.53%)
At close: May 08, 2025, 3:59 PM
12.44
-6.18%
Pre-market: May 09, 2025, 04:00 AM EDT
1.53% (1D)
| Bid | 12.44 |
| Market Cap | 1.82B |
| Revenue (ttm) | 2.5M |
| Net Income (ttm) | -639.71M |
| EPS (ttm) | -5.15 |
| PE Ratio (ttm) | -2.57 |
| Forward PE | -3.56 |
| Analyst | Buy |
| Ask | 14 |
| Volume | 1,097,642 |
| Avg. Volume (20D) | 1,725,506 |
| Open | 13.06 |
| Previous Close | 13.06 |
| Day's Range | 12.44 - 13.49 |
| 52-Week Range | 9.57 - 30.41 |
| Beta | 0.90 |
About ARWR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARWR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Arrowhead Pharmaceuticals Inc. is scheduled to release its earnings on May 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-10.37%
Arrowhead Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
2 months ago
-5.17%
Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.
3 weeks ago · businesswire.com
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial OfficerPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will reti...
2 months ago · seekingalpha.com
Arrowhead Pharmaceuticals: Progress During Adverse Market ConditionsArrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with...